184P - Clinical significance of angiopoietin-2 serum levels in non-small cell lung cancer

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Thoracic malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Ana Coelho
Authors A. Coelho1, A.M.F. Araujo2, R. Catarino1, M. Gomes1, A. Marques3, R. Medeiros1
  • 1Molecular Oncology Unit, Portuguese Intitute of Oncology Porto, 4100 - Porto/PT
  • 2Medical Oncology, Portuguese Institute of Oncology, 4200-003 - Porto/PT
  • 3Faculty Of Medicine, University of Porto, 4200 - Porto/PT



Tumor vasculature is a very promising target in NSCLC, with VEGF inhibitors as part of standard care in some patients. Angiopoietin-2 (Ang-2) plays critical roles in angiogenesis in concert with VEGF. High tumor Ang-2 expression has negative prognostic implications in lung cancer patients, especially when VEGF expression is high. The aim of this study was the evaluation of Ang-2 and VEGF serum levels in NSCLC and tumor stages and its comparison with healthy controls.

Patients and methods

The study included 30 controls, 145 NSCLC patients, (48 epidermoid, 73 adenocarcinomas, 19 undiferenciated NSCLC, 4 large cells and 1 mixed carcinoma), divided in 13 early and 132 advanced stages). Ang-2 and VEGF levels were evaluated in subject samples with R&D Quantikine ELISA Kit, according to manufacturer's instructions.


Ang-2 levels were significantly different in the control and case groups (Mann-Whitney test, p = 0.003). Mean concentration values were 2855.50 pmol/ml (SE 268.64) vs 4164.90 pmol/ml (SE 200.56), respectively. Regarding stage analysis, Ang-2 levels were also statistically different according to tumor stage (Mann-Whitney test, p = 0.016): mean 2824.64 pmol/ml (standard error 472.82) and 4202.57 pmol/ml (203.05) for early and advanced stages, respectively. VEGF levels were significantly different in the control and case groups (Mann-Whitney test, p = 0.001). Mean concentration values were 312.63 pmol/ml (standard error 59.62) vs 675.51 pmol/ml (standard error 55.30), respectively. Regarding stage analysis, there were no statistically significant differences between VEGF levels and tumor stage (Man-Whitney test, p = 0.197).


Angiogenesis inhibitors have obvious, yet modest, antitumor activity in NSCLC. Ang-2 seems to be a promising target of such inhibitors and its serum levels may be useful to predict which patients will benefit more with this type of treatment, surpassing the need to obtain tumor tissue samples to assess its levels of expression.


All authors have declared no conflicts of interest.